Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Study protocol

Gamma probe and ultrasound guided fine needle aspiration cytology of the sentinel node (GULF) trial - overview of the literature, pilot and study protocol

Authors: Charlotte M.C. Oude Ophuis, Lisa B. Koppert, Cécile de Monyé, Carolien H.M. van Deurzen, Senada Koljenović, Alexander C.J. van Akkooi, Cornelis Verhoef, Dirk J. Grünhagen

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

Sentinel node (SN) biopsy (SNB) detects clinically occult metastases of breast cancer and melanoma in 20–30%. Wound infections, seroma and lymph edema occur in up to 10%. Targeted ultrasound (US) of the SN, (with fine needle aspiration cytology (FNAC) if appropriate) has been investigated as a minimally invasive alternative, but reported sensitivity rates are too low to replace SNB. Our hypothesis is that the use of a handheld gamma probe concomitant with US may improve sensitivity.
Our aim is to provide an overview of the current literature on preoperative nodal staging of clinical N0 melanoma patients, report on a pilot, and present a study protocol for a minimally invasive alternative to the SNB: Gamma probe and Ultrasound guided Fine needle aspiration cytology of the sentinel node (GULF trial).

Methods

The GULF trial is a multicenter open single arm observational trial. Newly diagnosed cT1b-4N0M0 cutaneous melanoma or cT1-3N0M0 breast cancer patients, aged >18 years, presenting for SNB are eligible. 120 patients will be included for preoperative targeted gamma probe guided US and FNAC of the SN. Afterwards all patients proceed to surgical SNB. Primary endpoint is the sensitivity of FNAC. Secondary endpoints include SN identification rate and the histopathological compatibility of Core Needle Biopsy and FNAC vs. SNB. Secondary endpoints were investigated in a pilot with 10 FNACs and marker placements, and 10 FNACs combined with Core Needle Biopsy.

Results

A pilot in 20 patients showed that SN identification rate was 90%, supporting the feasibility of this technique.

Discussion

There is broad experience with US (in combination with FNAC) prior to SNB, but sensitivity and specificity are too low to completely abandon SNB. Promising alternative techniques potentially will replace SNB in the future but more evidence is needed in the form of prospective studies. Accurate identification of the SN for US-FNAC has been proven feasible in our pilot. When adequate sensitivity can be reached, US-FNAC provides a minimally invasive alternative for the surgical SNB procedure.

Trial registration

The GULF trial is registered in the Netherlands Trial Registry (NTR), ID: NRT5193. May 1st 2015.
Appendix
Available only for authorised users
Literature
1.
Wrightson WR, Wong SL, Edwards MJ, et al. Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg Oncol Jul 2003; 10(6):676-680.
2.
Biver-Dalle C, Puzenat E, Puyraveau M, et al. Sentinel lymph node biopsy in melanoma: our 8-year clinical experience in a single French institute (2002-2009). BMC Dermatol. 2012;12:21.CrossRefPubMedPubMedCentral
3.
Cook MG, Green MA, Anderson B, et al. The development of optimal pathological assessment of sentinel lymph nodes for melanoma. J Pathol Jul 2003; 200(3):314-319.
4.
Chakera AH, Hesse B, Burak Z, et al. EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. Eur J Nucl Med Mol Imaging Oct 2009; 36(10):1713-1742.
5.
Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - update 2016. Eur J Cancer. Jun 28 2016;63:201-217.
6.
van Akkooi AC, de Wilt JH, Verhoef C, Graveland WJ, van Geel AN, Kliffen M, Eggermont AM. High positive sentinel node identification rate by EORTC melanoma group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma. Eur J Cancer Feb 2006;42(3):372-380.
7.
Weaver DL, Ashikaga T, Krag DN, et al. Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med. Feb 3 2011;364(5):412-421.
8.
Weaver DL. Pathology evaluation of sentinel lymph nodes in breast cancer: protocol recommendations and rationale. Mod Pathol May 2010;23 Suppl 2:S26-S32.
9.
van der Ploeg AP, van Akkooi AC, Verhoef C, Eggermont AM. Completion lymph node dissection after a positive sentinel node: no longer a must? Curr Opin Oncol Mar 2013;25(2):152-159.
10.
van der Ploeg AP, van Akkooi AC, Schmitz PI, Koljenovic S, Verhoef C, Eggermont AM. EORTC melanoma group sentinel node protocol identifies high rate of submicrometastases according to Rotterdam criteria. Eur J Cancer Sep 2010;46(13):2414-2421.
11.
van Akkooi AC, de Wilt JH, Verhoef C, Eggermont AM. Isolated tumor cells and long-term prognosis of patients with melanoma. Ann Surg Oncol May 2008;15(5):1547-1548.
12.
de Wilt JH, van Akkooi AC, Verhoef C, Eggermont AM. Detection of melanoma micrometastases in sentinel nodes - the cons. Surg Oncol Sep 2008;17(3):175-181.
13.
Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. Jun 2016;17(6):757-767.
14.
de Boer M, van Deurzen CH, van Dijck JA, et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med. Aug 13 2009; 361(7):653-663.
15.
Hansen NM, Grube B, Ye X, Turner RR, Brenner RJ, Sim MS, Giuliano AE. Impact of micrometastases in the sentinel node of patients with invasive breast cancer. J Clin Oncol. Oct 1 2009;27(28):4679-4684.
16.
Meattini I, Desideri I, Saieva C, et al. Impact of sentinel node tumor burden on outcome of invasive breast cancer patients. Eur J Surg Oncol Oct 2014;40(10):1195-1202.
17.
van der Heiden-van der Loo M, Schaapveld M, Ho VK, Siesling S, Rutgers EJ, Peeters PH. Outcomes of a population-based series of early breast cancer patients with micrometastases and isolated tumour cells in axillary lymph nodes. Ann Oncol Nov 2013; 24(11):2794-2801.
18.
19.
Morton DL. Overview and update of the phase III multicenter selective Lymphadenectomy trials (MSLT-I and MSLT-II) in melanoma. Clin Exp Metastasis Oct 2012;29(7):699-706.
20.
Eggermont AM, Maio M, Robert C. Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies. Semin Oncol Jun 2015;42(3):429-435.
21.
Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol May 2015;16(5):522-530.
22.
Eggermont AM, Chiarion-Sileni V, Grob JJ. Correction to Lancet Oncol 2015; 16: 522-30. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. Jun 2015; 16(6):e262.
23.
Houssami N, Ciatto S, Turner RM, Cody HS, 3rd, Macaskill P. Preoperative ultrasound-guided needle biopsy of axillary nodes in invasive breast cancer: meta-analysis of its accuracy and utility in staging the axilla. Ann Surg Aug 2011;254(2):243-251.
24.
de Kanter AY, van Eijck CH, van Geel AN, et al. Multicentre study of ultrasonographically guided axillary node biopsy in patients with breast cancer. Br J Surg Nov 1999;86(11):1459-1462.
25.
Rossi CR, Mocellin S, Scagnet B, et al. The role of preoperative ultrasound scan in detecting lymph node metastasis before sentinel node biopsy in melanoma patients. J Surg Oncol Jun 2003;83(2):80-84.
26.
van Rijk MC, Teertstra HJ, Peterse JL, Nieweg OE, Olmos RA, Hoefnagel CA, Kroon BB. Ultrasonography and fine-needle aspiration cytology in the preoperative evaluation of melanoma patients eligible for sentinel node biopsy. Ann Surg Oncol Nov 2006;13(11):1511-1516.
27.
Catalano O. Critical analysis of the ultrasonographic criteria for diagnosing lymph node metastasis in patients with cutaneous melanoma: a systematic review. J Ultrasound Med. 2011;30(4):547–60.CrossRefPubMed
28.
Xing Y, Bronstein Y, Ross MI, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst. Jan 19 2011;103(2):129-142.
29.
Voit C, Kron M, Schafer G, et al. Ultrasound-guided fine needle aspiration cytology prior to sentinel lymph node biopsy in melanoma patients. Ann Surg Oncol Dec 2006;13(12):1682-1689.
30.
Voit CA, van Akkooi AC, Schafer-Hesterberg G, Schoengen A, Schmitz PI, Sterry W, Eggermont AM. Rotterdam criteria for sentinel node (SN) tumor burden and the accuracy of ultrasound (US)-guided fine-needle aspiration cytology (FNAC): can US-guided FNAC replace SN staging in patients with melanoma? J Clin Oncol. Oct 20 2009;27(30):4994-5000.
31.
Voit C, Van Akkooi AC, Schafer-Hesterberg G, et al. Ultrasound morphology criteria predict metastatic disease of the sentinel nodes in patients with melanoma. J Clin Oncol. Feb 10 2010; 28(5):847-852.
32.
Voit CA, Gooskens SLM, Siegel P, et al. Ultrasound-guided fine needle aspiration cytology as an addendum to sentinel lymph node biopsy can perfect the staging strategy in melanoma patients. Eur J Cancer. 2014;50(13):2280–8.CrossRefPubMed
33.
Voit CA, Oude Ophuis CMC, Ulrich J, van Akkooi ACJ, Eggermont AMM. Ultrasound of the sentinel node in melanoma patients: echo-free island is a discriminatory morphologic feature for node positivity. Melanoma Res. 2016;26(3):267–71.CrossRefPubMed
34.
Hinz T, Hoeller T, Wenzel J, Bieber T, Schmid-Wendtner MH. Real-time tissue elastography as promising diagnostic tool for diagnosis of lymph node metastases in patients with malignant melanoma: a prospective single-center experience. Dermatology. 2013;226(1):81–90.CrossRefPubMed
35.
Ogata D, Uematsu T, Yoshikawa S, Kiyohara Y. Accuracy of real-time ultrasound elastography in the differential diagnosis of lymph nodes in cutaneous malignant melanoma (CMM): a pilot study. Int J Clin Oncol Aug 2014;19(4):716-721.
36.
De Giorgi V, Gori A, Grazzini M, et al. Contrast-enhanced ultrasound: a filter role in AJCC stage I/II melanoma patients. Oncology (Switzerland). 2010;79(5–6):370–5.
37.
Stoffels I, Morscher S, Helfrich I, et al. Metastatic status of sentinel lymph nodes in melanoma determined noninvasively with multispectral optoacoustic imaging. Sci Transl Med. 2015;(7):317.
38.
Freesmeyer M, Winkens T, Opfermann T, Elsner P, Runnebaum I, Darr A. Real-time ultrasound and freehand-SPECT: experiences with sentinel lymph node mapping. Nuklearmedizin. 2014;53(6):259–64.CrossRefPubMed
39.
Bluemel C, Safak G, Cramer A, et al. Fusion of freehand SPECT and ultrasound: First experience in preoperative localization of sentinel lymph nodes. Eur J Nucl Med Mol Imaging. 2016;43(13):2304–2312
40.
Fujiwara M, Mizukami T, Suzuki A, Fukamizu H. Sentinel lymph node detection in skin cancer patients using real-time fluorescence navigation with indocyanine green: preliminary experience. J Plast Reconstr Aesthet Surg Oct 2009;62(10):e373-e378.
41.
Brouwer OR, Buckle T, Vermeeren L, et al. Comparing the hybrid fluorescent-radioactive tracer indocyanine green-99mTc-nanocolloid with 99mTc-nanocolloid for sentinel node identification: a validation study using lymphoscintigraphy and SPECT/CT. J Nucl Med Jul 2012;53(7):1034-1040.
42.
Gilmore DM, Khullar OV, Gioux S, Stockdale A, Frangioni JV, Colson YL, Russell SE. Effective low-dose escalation of indocyanine green for near-infrared fluorescent sentinel lymph node mapping in melanoma. Ann Surg Oncol Jul 2013;20(7):2357-2363.
43.
Cloyd JM, Wapnir IL, Read BM, Swetter S, Greco RS. Indocyanine green and fluorescence lymphangiography for sentinel lymph node identification in cutaneous melanoma. J Surg Oncol Dec 2014;110(7):888-892.
44.
Korn JM, Tellez-Diaz A, Bartz-Kurycki M, Gastman B. Indocyanine green SPY elite-assisted sentinel lymph node biopsy in cutaneous melanoma. Plast Reconstr Surg Apr 2014;133(4):914-922.
45.
Namikawa K, Tsutsumida A, Tanaka R, Kato J, Yamazaki N. Limitation of indocyanine green fluorescence in identifying sentinel lymph node prior to skin incision in cutaneous melanoma. Int J Clin Oncol Feb 2014;19(1):198-203.
46.
Hollerweger A, Macheiner P, Hubner E, Gritzmann N. Axillary sentinel lymph-node biopsy: gamma probe assisted sonographic localisation. Ultraschall Med Feb 2006;27(1):34-39.
47.
Whelehan P, Vinnicombe SJ, Brown DC, McLean D, Evans A. Accuracy of non-operative identification of the sentinel lymph node using combined gamma and ultrasound scanning. Clin Radiol Aug 2014;69(8):849-852.
48.
Testori A, Meroni S, Moscovici OC, et al. Surgical sentinel lymph node biopsy in early breast cancer. Could it be avoided by performing a preoperative staging procedure? A pilot study. Med Sci Monit Sep 2012;18(9):CR543-CR549.
49.
Motomura K, Inaji H, Komoike Y, et al. Gamma probe and ultrasonographically-guided fine-needle aspiration biopsy of sentinel lymph nodes in breast cancer patients. Eur J Surg Oncol Mar 2001;27(2):141-145.
50.
Bostick P, Essner R, Glass E, et al. Comparison of blue dye and probe-assisted intraoperative lymphatic mapping in melanoma to identify sentinel nodes in 100 lymphatic basins. Arch Surg Jan 1999;134(1):43-49.
51.
Bluemel C, Herrmann K, Giammarile F, et al. EANM practice guidelines for lymphoscintigraphy and sentinel lymph node biopsy in melanoma. Eur J Nucl Med Mol Imaging Oct 2015;42(11):1750-1766.
52.
van der Ploeg AP, van Akkooi AC, Haydu LE, et al. The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients. Eur J Cancer Jan 2014;50(1):111-120.
53.
Houvenaeghel G, Classe JM, Garbay JR, et al. Prognostic value of isolated tumor cells and micrometastases of lymph nodes in early-stage breast cancer: a French sentinel node multicenter cohort study. Breast Oct 2014;23(5):561-566.
54.
Eggermont AM, Suciu S, Rutkowski P, et al. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: ulceration of primary is key determinant for IFN-sensitivity. Eur J Cancer Mar 2016;55:111-121.
55.
Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. Feb 13 2014;370(7):599-609.
56.
van Akkooi AC. Sentinel node followed by completion lymph node dissection versus nodal observation: staging or therapeutic? Controversy continues despite final results of MSLT-1. Melanoma Res Aug 2014;24(4):291-294.
57.
Thomas JM. Sentinel-node biopsy in melanoma. N Engl J Med. May 29 2014; 370(22):2148.
58.
Hinz T, Wilsmann-Theis D, Buchner A, et al. High-resolution ultrasound combined with power Doppler sonography can reduce the number of sentinel lymph node biopsies in cutaneous melanoma. Dermatology 2011;222(2):180-188.
59.
Thompson JF, Haydu LE, Sanki A, Uren RF. Ultrasound assessment of lymph nodes in the management of early-stage melanoma. J Surg Oncol Sep 2011;104(4):354-360.
60.
Sanki A, Uren RF, Moncrieff M, Tran KL, Scolyer RA, Lin HY, Thompson JF. Targeted high-resolution ultrasound is not an effective substitute for sentinel lymph node biopsy in patients with primary cutaneous melanoma. J Clin Oncol. Nov 20 2009; 27(33):5614-5619.
61.
Rossi CR, Scagnet B, Vecchiato A, et al. Sentinel node biopsy and ultrasound scanning in cutaneous melanomaclinical and technical considerations. Eur J Cancer. 2000;36(7):895–900.CrossRefPubMed
62.
Hocevar M, Bracko M, Pogacnik A, Vidergar-Kralj B, Besic N, Zgajnar J, Music MM. The role of preoperative ultrasonography in reducing the number of sentinel lymph node procedures in melanoma. Melanoma Res Dec 2004;14(6):533-536.
63.
Testori A, Lazzaro G, Baldini F, et al. The role of ultrasound of sentinel nodes in the pre- and post-operative evaluation of stage I melanoma patients. Melanoma Res Jun 2005;15(3):191-198.
64.
Starritt EC, Uren RF, Scolyer RA, Quinn MJ, Thompson JF. Ultrasound examination of sentinel nodes in the initial assessment of patients with primary cutaneous melanoma. Ann Surg Oncol. 2005;12(1):18–23.CrossRefPubMed
65.
Voit CA, Schaefer G, Schoengen A, et al. Ultrasound (US) and US-guided fine needle aspiration cytology (FNAC) prior to sentinel lymph node biopsy (SLNB) in melanoma patients: accuracy of US-FNAC and lack of further improvement by RT-PCR of the aspirate. J Clin Oncol Jun 2006;24(18):467S-467S.
66.
Sibon C, Chagnon S, Tchakerian A, et al. The contribution of high-resolution ultrasonography in preoperatively detecting sentinel-node metastases in melanoma patients. Melanoma Res Aug 2007;17(4):233-237.
67.
Kunte C, Schuh T, Eberle JY, et al. The use of high-resolution ultrasonography for preoperative detection of metastases in sentinel lymph nodes of patients with cutaneous melanoma. Dermatol Surg Nov 2009;35(11):1757-1765.
68.
Chai CY, Zager JS, Szabunio MM, Marzban SS, Chau A, Rossi RM, Sondak VK. Preoperative ultrasound is not useful for identifying nodal metastasis in melanoma patients undergoing sentinel node biopsy: preoperative ultrasound in clinically node-negative melanoma. Ann Surg Oncol Apr 2012; 19(4):1100-1106.
69.
Marone U, Catalano O, Caracò C, et al. Can high-resolution ultrasound avoid the sentinel lymph-node biopsy procedure in the staging process of patients with stage I-II cutaneous melanoma? Ultraschall Med. 2012;33(7):E179–85.CrossRefPubMed
70.
Pilko G, Zgajnar J, Music M, Hocevar M. Lower tumour burden and better overall survival in melanoma patients with regional lymph node metastases and negative preoperative ultrasound. Radiol Oncol. 2012;46(1):60–8.CrossRefPubMed
71.
Stoffels I, Dissemond J, Poeppel T, et al. Advantages of preoperative ultrasound in conjunction with lymphoscintigraphy in detecting malignant melanoma metastases in sentinel lymph nodes: a retrospective analysis in 221 patients with malignant melanoma AJCC stages I and II. J Eur Acad Dermatol Venereol Jan 2012; 26(1):79-85.
72.
Hinz T, Voth H, Ahmadzadehfar H, Hoeller T, Wenzel J, Bieber T, Schmid-Wendtner MH. Role of high-resolution ultrasound and PET/CT imaging for preoperative characterization of sentinel lymph nodes in cutaneous melanoma. Ultrasound Med Biol Jan 2013; 39(1):30-36.
73.
Ulrich J, van Akkooi AC, Eggermont AM, Voit CA. [Sonographic criteria for diagnosing sentinel node metastases in melanoma patients]. Ultraschall Med Apr 2015; 36(2):149-153.
Metadata
Title
Gamma probe and ultrasound guided fine needle aspiration cytology of the sentinel node (GULF) trial - overview of the literature, pilot and study protocol
Authors
Charlotte M.C. Oude Ophuis
Lisa B. Koppert
Cécile de Monyé
Carolien H.M. van Deurzen
Senada Koljenović
Alexander C.J. van Akkooi
Cornelis Verhoef
Dirk J. Grünhagen
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3236-2

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue

Research article

Chemoradiotherapy versus surgery followed by postoperative radiotherapy in tonsil cancer: Korean Radiation Oncology Group (KROG) study

Research article

Adipokines, insulin resistance, and adiposity as a predictors of metabolic syndrome in child survivors of lymphoma and acute lymphoblastic leukemia of a developing country

Case report

Hybrid peripheral nerve sheath tumors: report of five cases and detailed review of literature

Research article

Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01–2014)

Research article

Lysosome trafficking is necessary for EGF-driven invasion and is regulated by p38 MAPK and Na+/H+ exchangers

Research article

Prevention of liver tumor formation in woodchucks with established hepatocellular carcinoma by treatment with cationic liposome-DNA complexes
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits